InflaRx (NASDAQ:IFRX) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of InflaRx (NASDAQ:IFRX) in a report published on Friday morning,Benzinga reports. They currently have a $8.00 target price on the stock.

InflaRx Price Performance

Shares of IFRX opened at $2.24 on Friday. InflaRx has a one year low of $1.16 and a one year high of $2.82. The company has a market cap of $131.90 million, a PE ratio of -2.07 and a beta of 1.67. The stock has a 50-day moving average of $1.93 and a 200-day moving average of $1.67.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.